Survival analysis of patients with Sjögren’s syndrome in Turkey: a tertiary hospital-based study
- 124 Downloads
This study was conducted to determine long-term survival rates and the factors associated with mortality in Turkish primary Sjögren syndrome (pSS) patients.
All patients diagnosed with pSS between 2004 and 2014 were included in this study. By January 2019, all subjects still living by the end of the study, as well as any death, were identified. Survival rates and standard mortality rates (SMRs) using general population mortality data were calculated. Mortality-related factors were determined by univariate and multivariate analysis.
During follow-up, 33 cases of 372 pSS patients resulted in death (8.9%). Of those patients, they were typically older at disease onset, at recruitment, and had shorter follow-up times (p < 0.001 for all). The overall SMR of all pSS patients compared with the general population was 2.11 (95% confidence interval (CI) 1.39–2.83). Male pSS patients had a higher SMR than that of general male patients. Overall survival rates were 97.8% at five years, 90.2% at 10 years, and 87.1% at 15 years in patients with pSS. The survival rate of pSS patients was significantly lower than the general Turkish population (p = 0.011). Multivariate Cox regression analysis showed that older age at disease onset and the presence of interstitial lung disease (ILD) were independent risk factors for mortality.
• Mortality in Sjögren’s syndrome.
KeywordsMortality Prognosis Sjögren’s syndrome Standard mortality rates Survival
This study is supported by Akdeniz University Scientific Research Projects Unit.
VY contributed to conception and design of the study, analysis and interpretation of data, and drafting the manuscript; MG, İU, BA, ŞO, EG and FE collected data and reviewed the literature; ET was responsible for the revision of the manuscript for important intellectual content; all authors issued approval for the final version to be submitted.
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the World Medical Association Helsinki Declaration 2018 and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of Akdeniz University School of Medicine (Approval number:2019-534).
- 10.Palm Q, Garen T, Enger TB, Jensen JL, Lund MB, Aalokken TM, Gran JT (2013) Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality-a retrospective study based on registry data. Rheumatology (Oxford) 52(1):173–179. https://doi.org/10.1093/rheumatology/kes311 CrossRefGoogle Scholar
- 15.Brito-Zerón P, Kostov B, Solans R, Fraile G, Suárez-Cuervo C, Casanovas A, Rascón FJ, Qanneta R, Pérez-Alvarez R, Ripoll M, Akasbi M, Pinilla B, Bosch JA, Nava-Mateos J, Díaz-López B, Morera-Morales ML, Gheitasi H, Retamozo S, Ramos-Casals M, SS Study Group, Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI) (2016) Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis 75(2):348–355. https://doi.org/10.1136/annrheumdis-2014-206418 CrossRefPubMedGoogle Scholar
- 18.Kim HJ, Kim KH, Hann HJ, Han S, Kim Y, Lee SH, Kim DS, Ahn HS (2017) Incidence, mortality, and causes of death in physician-diagnosed primary Sjögren’s syndrome in Korea: a nationwide, population-based study. Semin Arthritis Rheum 47(2):222–227. https://doi.org/10.1016/j.semarthrit.2017.03.004 CrossRefPubMedGoogle Scholar
- 19.Kabasakal Y, Kitapçıoğlu G, Karabulut G, Tezcan M, Balkarlı A, Aksoy A, Yavuz Ş, Yılmaz S, Kaşifoğlu T, Kalyoncu U, Dalkılıç E, Tufan A, Mercan R, Yıldız F, Şentürk T, Önen F, Bes C, Erken E, Tunç E, Kamalı S, Tarhan E, Yazıcı A, Düzgün N, Bıçakçıgil M, Yılmaz S, Özmen M, Öcal L, Alibaz-Öner F, Solmaz D, Çobankara V, Nalbant S, Kasapoğlu Günal E, Kaşkari D, Göker B (2017) Criteria sets for primary Sjogren’s syndrome are not adequate for those presenting with extraglandular organ involvements as their dominant clinical features. Rheumatol Int 37(5):675–684. https://doi.org/10.1007/s00296-017-3691-8 CrossRefPubMedGoogle Scholar
- 20.Shiboski SC, Shiboski CH, Criswell LA, Baer AN, Challacombe S, Lanfranchi H, Schiødt M, Umehara H, Vivino F, Zhao Y, Dong Y, Greenspan D, Heidenreich AM, Helin P, Kirkham B, Kitagawa K, Larkin G, Li M, Lietman T, Lindegaard J, McNamara N, Sack K, Shirlaw P, Sugai S, Vollenweider C, Whitcher J, Wu A, Zhang S, Zhang W, Greenspan JS, Daniels TE, Sjögren’s International Collaborative Clinical Alliance (SICCA) Research Groups (2012) American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance Cohort. Arthritis Care Res 64(4):475–487CrossRefGoogle Scholar
- 21.Daniels TE, Cox D, Shiboski CH, Schiødt M, Wu A, Lanfranchi H, Umehara H, Zhao Y, Challacombe S, Lam MY, de Souza Y, Schiødt J, Holm H, Bisio PAM, Gandolfo MS, Sawaki T, Li M, Zhang W, Varghese-Jacob B, Ibsen P, Keszler A, Kurose N, Nojima T, Odell E, Criswell LA, Jordan R, Greenspan JS, Sjögren’s International Collaborative Clinical Alliance Research Groups (2011) Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren’s syndrome among 1,726 registry participants. Arthritis Rheum 63:2021–2030CrossRefGoogle Scholar
- 22.American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002) This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277–304CrossRefGoogle Scholar
- 25.Maciel G, Crowson CS, Matteson EL, Cornec D (2017) Incidence and mortality of physician-diagnosed primary Sjögren syndrome: time trends over a 40-year period in a population-based US cohort. Mayo Clin Proc 92(5):734–743. https://doi.org/10.1016/j.mayocp.2017.01.020 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, Alvo-Alen J, Jiménez-Alonso J, Micó ML, Beltrán J, Belenguer R, Pallarés L, GEMESS Study Group (2008) Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 87(4):210–219. https://doi.org/10.1097/MD.0b013e318181e6af CrossRefGoogle Scholar
- 31.Nannini C, Jebakumar AJ, Crowson CS, Ryu JH, Matteson EL (2013) Primary Sjogren’s syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open 3(11):e003569. https://doi.org/10.1136/bmjopen-2013-003569 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Enomoto Y, Takemura T, Hagiwara E, Iwasawa T, Fukuda Y, Yanagawa N, Sakai F, Baba T, Nagaoka S, Ogura T (2013) Prognostic factors in interstitial lung disease associated with primary Sjogren’s syndrome: a retrospective analysis of 33 pathologically-proven cases. PLoS One 8:e73774. https://doi.org/10.1371/journal.pone.0073774 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Gao H, Zhang XW, He J, Zhang J, An Y, Sun Y, Jia RL, Li SG, Zhang LJ, Li ZG (2018) Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients: a case-control study. Medicine (Baltimore) 97(24):e11003. https://doi.org/10.1097/MD.0000000000011003 CrossRefGoogle Scholar
- 38.Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, Løkke A, Bendstrup E, Ellingsen T (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76(10):1700–1706. https://doi.org/10.1136/annrheumdis-2017-211138 CrossRefPubMedGoogle Scholar
- 43.Flores-Chávez A, Kostov B, Solans R, Fraile G, Maure B, Feijoo-Massó C, Rascón FJ, Pérez-Alvarez R, Zamora-Pasadas M, García-Pérez A, Lopez-Dupla M, Duarte-Millán MÁ, Ripoll M, Fonseca-Aizpuru E, Guisado-Vasco P, Pinilla B, dela Red G, Chamorro AJ, Morcillo C, Fanlo P, Soto-Cárdenas MJ, Retamozo S, Ramos-Casals M, Brito-Zerón P, GEAS-SS SEMI Registry (2018) Severe, life-threatening phenotype of primary Sjögren’s syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol 36 Suppl 112(3):121–129PubMedGoogle Scholar